TD Cowen Maintains Buy on Revvity, Raises Price Target to $175
10/13/2026
Impact: 70
Healthcare
TD Cowen analyst Dan Brennan has maintained a Buy rating on Revvity (NYSE: RVTY) and increased the price target from $130 to $175.
AI summary, not financial advice
Share: